Abstract
The search for a “second-generation” Pt compound to supersede cisplatin has been conducted in many laboratories (1–13). For the past six years, the efforts at Bristol-Myers have been focused on finding analogs with improved antitumor activities and reduced toxicities relative to cisplatin as judged by their effects in animal models (1, 10, 11). The present discussion will be limited to a review of antitumor test results obtained with those Pt compounds now undergoing clinical evaluation, and a few other analogs of potential interest.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bradner WT, Rose WC, Huftalen JB. 1980. Antitumor activity of platinum analogs. In Cisplatin: Current Status and New Developments (Prestayko AW, Croke ST, and Carter SK, eds.), Academic Press, Inc., New York, pp. 171–182.
Burchenal JH, Kalaher K, Dew K, Lokys L, Gale G. 1978. Studies of cross-resistance, synergistic combinations and blocking of activity of platinum derivatives. Biochime 60: 961–965.
Cleare MJ, Hydes PC, Malerbi BW, Watkins DM. 1978. Anti-tumour platinum complexes: relationships between chemical properties and activity. Biochimie 60:835–850.
Connors TA, Cleare MJ, Harrap KR. 1979. Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat. 63:1499–1502.
Craciunescu DG, Doadrio A, Furlani A, Scarcia V. 1982. Structure-antitumor activity relationships for new platinum complexes. Chem.-Biol. Interactions 42:153–164.
Hall LM, Speer RJ, Ridgway HJ, Norton SJ. 1979. Unsymmetrical C-substituted ethylenediamine platinum coordination complexes: synthesis and activity against mouse leukemia L1210. J. Inorg. Biochem. 11:139–149.
Kidani Y, Okamoto K, Noji M, Tashiro T. 1978. Antitumor activity of platinum (II) complexes of 1-amino-2-amino-methylcyclohexane isomers. Gann 69:863–864.
Meishen SJ, Gale GR, Lake LM, Frangakis CJ, Rosenblum MG, Walker Jr., EM, Atkins LM, Smith AB. 1976. Antileukemic properties of organoplatinum complexes. J. Natl. Cancer Inst. 57:841–845.
Pera Jr., MF, Sessford D, Roberts JJ. 1982. Toxicity of cisplatin and hydroxymalonatodiammine platinum (II) towards mouse bone marrow and B16 melanoma in relation to DNA binding in vivo. Biochem. Pharmacol. 31:2273–2278.
Prestayko AW, Bradner WT, Huftalen JB, Rose WC, Schurig JE, Clear MJ, Hydes PC, Crooke ST. 1979. Antileukemic (L1210) activity and toxicity of cis-dichlorodiammineplatinum (II) analogs. Cancer Treat. Rep 63:1503–1508.
Rose WC, Schurig JE, Huftalen JB, Bradner WT. 1982. Antitumor activity and toxicity of cisplatin analogs. Cancer Treat. Rep. 66:135–146.
Sheperd R, Kusnierczyk H, Jones M, Harrap KR. 1980. Critera for the selection of second-generation platinum compounds. Br. J. Cancer 42:668–676.
Wolpert-DeFillippes MK. 1980. Antitumor activity of cisplatin analogs.In Cisplatin: Current Status and New Developments (Prestayko AW, Crooke ST and Carter SK, eds.), Academic Press, Inc., New York, pp 183–191.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Rose, W.C., Bradner, W.T. (1984). Experimental Antitumor Activity of Platinum Coordination Complexes. In: Hacker, M.P., Douple, E.B., Krakoff, I.H. (eds) Platinum Coordination Complexes in Cancer Chemotherapy. Developments in Oncology, vol 17. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2837-7_19
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2837-7_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-89838-619-6
Online ISBN: 978-1-4613-2837-7
eBook Packages: Springer Book Archive